|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00712777 |
|
Date of registration:
|
08/07/2008 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism
|
|
Scientific title:
|
Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism |
|
Date of first enrolment:
|
March 2008 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
http://clinicaltrials.gov/show/NCT00712777 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Austria
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Men aged between 19 and 35 years, nonsmokers
- Normal findings in the medical history and physical examination unless the
investigator considers an abnormality to be clinically irrelevant
- IOP between 12 and 16 mmHg
- Normal ophthalmic findings, ametropia < 3 Dpt.
- Results of alpha-2B receptor genotyping; subjects who fall within one of the
following groups: group 1: homozygote mutant: I/I (n=40); group 2: homozygote mutant:
D/D (n=40)
Exclusion Criteria:
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical
trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- History of hypersensitivity to the trial drug or to drugs with a similar chemical
structure
- History or presence of gastrointestinal, liver or kidney disease, or other conditions
known to interfere with, distribution, metabolism or excretion of study drugs
- Blood donation during the previous 3 weeks
Age minimum:
19 Years
Age maximum:
35 Years
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Intraocular Pressure
|
|
Ocular Physiology
|
|
Intervention(s)
|
|
Drug: Brimonidine 0.2 %
|
|
Primary Outcome(s)
|
|
alpha-2B receptor genotyping
[Time Frame: 20 minutes]
|
|
Intraocular pressure (IOP)
[Time Frame: in total 10 minutes]
|
|
Secondary ID(s)
|
|
OPHT-230408
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|